Shares of LightPath Technologies surged 7.7% to $10.07 on September 17 after the Orlando-based infrared optics maker announced it won a funded prototype agreement under the Pentagon's CLEAR program, a competitive process designed to fast-track alternatives to materials sourced from adversary nations. The stock had been drifting lower over the prior week from $9.68 to $9.39, making the pop notable — but the question for investors is whether a single undisclosed-value contract can sustain momentum for a company with a market cap still under $100 million. LightPath Lands a Pentagon Glass Deal Ahead of a Looming Germanium Ban — But Is the Stock Pricing In Revenue That Hasn't Arrived?
Shares of LightPath Technologies jumped 7.7% to $10.07 after the small infrared-optics maker announced it won a funded prototype agreement from the Department of War, validating its bet that U.S. defense programs will need to replace Chinese-sourced germanium — a key material in thermal imaging — before a hard deadline hits. The question now: how much real revenue this contract can deliver to a company still running at a loss.
A Ticking Clock Forces the Pentagon's Hand. Many defense infrared systems rely on germanium, for which China is the dominant global supplier. China has imposed export controls on the metal since 2023, and the 2026 National Defense Authorization Act added germanium to restricted materials, directing the Pentagon to eliminate reliance on adversary nations for optical glass.
The CLEAR program aims to develop domestic alternatives as new U.S. sourcing restrictions take effect in December 2027. That 15-month runway gives LightPath a regulatory tailwind few small defense suppliers enjoy.
LightPath Has the Only Licensed Substitute. LightPath is exclusively licensed by the U.S. Department of Defense to manufacture its chalcogenide glass alternative to germanium.
One variant is already fully qualified and field-deployed in multiple systems.
Under federal law, a competitively awarded prototype project that is successfully completed may be eligible for follow-on production contracts without further competition — a potential express lane to larger orders.
The Business Is Growing Fast, but Profits Are Still Elusive. Revenue grew 93% to $71.7 million in fiscal 2026, with Q4 hitting a record $21.2 million.
Adjusted EBITDA swung from a $5.1 million loss to a $4.2 million profit, and backlog finished at $110.9 million, up 197%. Still, the company posted a Q4 net loss of $4.1 million , and management offered no formal fiscal 2027 guidance. LightPath is also exiting China, agreeing to sell its subsidiary there for $4.5 million , a move that simplifies the story but removes near-term cash flow.
No Dollar Amount Means Investors Are Trading on Potential. The company disclosed no contract value for the CLEAR award. A prior Phase 2 qualification contract totaled roughly $0.5 million — meaningful for validation, not for the income statement. Management says growth will come from programs moving into production, including counter-drone systems and missile seekers, with two post-year-end orders totaling $24 million slated for 2027 delivery. The real payoff depends on whether today's prototype becomes tomorrow's production standard before the December 2027 deadline reshapes the supply chain.